Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
Portfolio Pulse from Vandana Singh
Senator Bernie Sanders has urged the U.S. Department of Health and Human Services (HHS) to address the high cost of Eisai Co Ltd and Biogen Inc's Alzheimer's treatment Leqembi, calling its $26,500 annual price tag 'unconscionable'. Sanders suggested breaking the patent monopoly or restricting the amount paid by Medicare and Medicaid Services for the drug.
June 08, 2023 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Bernie Sanders' call to address the high cost of Biogen's Alzheimer's treatment Leqembi may put pressure on the company to lower the price or face potential regulatory actions.
Senator Sanders' call to address the high cost of Leqembi may lead to regulatory actions that could impact Biogen's revenue from the drug. This could negatively affect the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
NEGATIVE IMPACT
Eisai Co Ltd may face pressure to lower the price of its Alzheimer's treatment Leqembi following Bernie Sanders' call to address the high cost, potentially leading to regulatory actions.
Senator Sanders' call to address the high cost of Leqembi may lead to regulatory actions that could impact Eisai's revenue from the drug. This could negatively affect the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50